Author:
Tombal Bertrand,Miller Kurt,Boccon-Gibod Laurent,Schröder Fritz,Shore Neal,Crawford E. David,Moul Judd,Jensen Jens-Kristian,Kold Olesen Tine,Persson Bo-Eric
Reference30 articles.
1. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?;Van Poppel;Urology,2008
2. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6mg and 10.8mg: results of a randomized open-label trial;Zinner;Urology,2004
3. Comparison of single-agent androgen suppression for advanced prostate cancer;Lepor;Rev Urol,2005
4. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America;Gittelman;J Urol,2008
5. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker—results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer;Van Poppel;Eur Urol,2008
Cited by
122 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献